Redhill Biopharma (RDHL) Expected to Announce Quarterly Earnings on Monday

Redhill Biopharma (NASDAQ:RDHL) is expected to be issuing its H2 24/25 resultson Monday, March 30th. Analysts expect Redhill Biopharma to post earnings of ($352.8571) per share and revenue of $24.2860 million for the quarter. Investors can check the company’s upcoming H2 24/25 earning summary page for the latest details on the call scheduled for Wednesday, April 8, 2026 at 6:00 PM ET.

Redhill Biopharma Stock Down 4.0%

Shares of NASDAQ RDHL opened at $0.75 on Friday. The stock’s 50-day simple moving average is $1.02 and its two-hundred day simple moving average is $1.26. Redhill Biopharma has a twelve month low of $0.75 and a twelve month high of $3.31. The firm has a market capitalization of $3.83 million, a P/E ratio of 0.00 and a beta of 4.91.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Redhill Biopharma in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Redhill Biopharma presently has an average rating of “Sell”.

About Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.